Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy that targets the Wilms tumor 1 (WT1) protein and addresses hematologic malignancies and solid tumors. Its second major product, SLS009 (tambiciclib), is a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor under development for cancer treatment. Sellas maintains strategic partnerships with prominent institutions, including a collaboration with Merck & Co. to evaluate GPS in combination with the PD-1 blocker pembrolizumab in clinical trials, a licensing agreement with Memorial Sloan Kettering Cancer Center for GPS development, and partnerships with GenFleet Therapeutics and 3D Medicines for commercialization rights in specific geographic regions. Founded in 2012 and headquartered in New York, New York, the company advances its pipeline through clinical-stage development programs targeting cancer patients with limited treatment options.